The use of exenatide in severely burned pediatric patients. - Wikidata - awgldk - TriplyDB

The use of exenatide in severely burned pediatric patients.

The use of exenatide in severely burned pediatric patients.

http://www.wikidata.org/entity/Q34153353

about

Burns: an update on current pharmacotherapy Clinical review: Glucose control in severely burned patients - current best practice.The potential role of incretin therapy in the hospital setting.Bench-to-bedside review: the gut as an endocrine organ in the critically ill The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?Glucose metabolism in critically ill patients: are incretins an important player?Glucose control in non-critically ill inpatients with diabetes: towards closed-loop.Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes.Nutrition and anabolic pharmacotherapies in the care of burn patients.Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.The metabolic stress response to burn trauma: current understanding and therapies.Glycemic variability: Clinical implications.Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards.

P2860

Q24618730-A0188BD9-9294-4EFE-B534-F84720E5812E Q33750033-016B54F7-442C-4368-B129-D43B3BE933C1 Q33792390-C43A1708-5DC6-41F3-9CC2-8BB8B2009665 Q35559137-00862418-29A4-455A-8391-6B318A43B4E4 Q35559222-22BE5EB8-B317-48AF-8AA8-EDFD54FA7571 Q35567284-97CAFFF1-7500-4567-87E3-1C6B2B2488DF Q36942108-8F03DF4A-E680-49B1-83F9-196F7ADC1264 Q37820839-90DC4D63-4753-464B-B448-8C87F9F1EC63 Q38142955-58E197D3-5FF2-427A-9176-BFD998133230 Q38165285-0D1F46EC-0C4A-4C7B-B783-31AE2AB0E805 Q38303079-97CCE6DA-1A68-4F56-9ADC-F0381B392C9F Q38326632-B09B040B-6BF5-41B3-9EFD-F3E8651F919C Q38683079-550F579F-BD79-444A-8045-D1CC1AA41E7B Q38972966-5BFAE852-B66C-4357-9218-B5097043F8E3 Q39364360-3094D576-511D-40EF-9418-0774BB8DB193 Q41886708-3B1E91AC-C7E8-45E2-A5A1-7FFFBEDCDB7B Q54948267-47390689-7BBC-4937-ABAB-FC04C0C413F1

P2860

The use of exenatide in severely burned pediatric patients.

http://www.wikidata.org/entity/Q34153353

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The use of exenatide in severely burned pediatric patients.

@ast

The use of exenatide in severely burned pediatric patients.

@en

The use of exenatide in severely burned pediatric patients.

@nl

type

label

The use of exenatide in severely burned pediatric patients.

@ast

The use of exenatide in severely burned pediatric patients.

@en

The use of exenatide in severely burned pediatric patients.

@nl

prefLabel

The use of exenatide in severely burned pediatric patients.

@ast

The use of exenatide in severely burned pediatric patients.

@en

The use of exenatide in severely burned pediatric patients.

@nl

P1433

Q34153353-D5717B96-E768-431C-B7B1-9E53B5B931FE

P1476

Q34153353-DFF8EB8E-C372-49DF-915A-1A76A9701473

P2093

Q34153353-12932CA8-C2D7-4462-A98C-894CCCA0FE1A

Q34153353-1B9CC502-EA39-4B37-858A-74D3F9D3B66D

Q34153353-37D62CD2-A3EE-4DD1-B0BF-9DD09E168069

Q34153353-5A9F8CC2-3E01-4E1B-A506-6BAF76B3FA1F

Q34153353-5BC206F7-4E49-46AD-BA62-26A018C3CFEC

Q34153353-B0B0B8F4-C1CF-47FF-B645-80F5954CB0F5

Q34153353-CF5A34E3-7EE5-4E46-924B-E65EEAB25E71

Q34153353-D4E25581-B75F-4189-8EF2-F96879A6F11F

Q34153353-DF4C8259-E440-4DC0-BD57-C9A3986B1F48

Q34153353-ED6C15EF-36BC-4313-A9CF-B3F036DBEAF1

P2860

Q34153353-173008A2-54E7-48C0-A32B-C4F810E16C44

Q34153353-26AABA12-6C9E-4B3C-A9C0-5A47B2DA7F76

Q34153353-2B0E7221-209C-49E6-BD85-8BB3D802873B

Q34153353-33CE9C05-5BA2-4720-96BB-C4FCAFA4C494

Q34153353-3888B321-97D7-4A08-B398-F60E1411C71B

Q34153353-42C25F65-3074-4E34-8424-424FFDCB4A7C

Q34153353-4F81260E-68A9-4841-8C46-C47A21260ED6

Q34153353-52E48FA6-F85C-4666-BFA4-CFD6D2C094B4

Q34153353-554431D6-C1E1-4EA0-9DE3-4F19C637F0E4

Q34153353-564789AE-A6F8-4170-8236-C2A7C473D2B9

P2888

Q34153353-3F1063E4-1B53-4A40-9837-514FA016806C

P304

Q34153353-A42780F1-DB44-4D44-AB23-54D3E5C08711

P31

Q34153353-4649F08A-2105-43F8-885E-EDC2755DA8D7

P356

Q34153353-0A3412BB-6955-4044-B863-634627AAB83F

P433

Q34153353-6620AAF3-DC48-4A36-8191-E66237281CB4

P478

Q34153353-85440D83-2CFD-4ADA-8D6F-87C60AE8705E

P577

Q34153353-C0845D48-A3D2-48D1-AC1E-8E6B717303AC

P5875

Q34153353-B0F672F8-EBD0-435A-BA58-41EA3F5F501A

P6179

Q34153353-371187D8-A3ED-41C2-81C7-5DFAD9A7E67E

P698

Q34153353-335978C8-8CD8-46F7-AF82-48B624C1AA37

P932

Q34153353-0B2A8BF4-2648-4402-8229-B204EAC87A1A

P356

P1433

P1476

The use of exenatide in severely burned pediatric patients.

@en

P2093

Ahmed M Al-Mousawi

http://www.w3.org/2001/XMLSchema#string

David N Herndon

http://www.w3.org/2001/XMLSchema#string

Felicia N Williams

http://www.w3.org/2001/XMLSchema#string

Gabriel A Mecott

http://www.w3.org/2001/XMLSchema#string

Gabriela A Kulp

http://www.w3.org/2001/XMLSchema#string

Haidy G Rivero

http://www.w3.org/2001/XMLSchema#string

Ludwik K Branski

http://www.w3.org/2001/XMLSchema#string

Marc G Jeschke

http://www.w3.org/2001/XMLSchema#string

Natasha C Brooks

http://www.w3.org/2001/XMLSchema#string

Robert Kraft

http://www.w3.org/2001/XMLSchema#string

P2860

A Biometric Study of Human Basal Metabolism

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data

Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control.

Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial.

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

New methods for calculating metabolic rate with special reference to protein metabolism.

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.

P2888

P304

R153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC9222

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45628694

http://www.w3.org/2001/XMLSchema#string

P6179

1053662740

http://www.w3.org/2001/XMLSchema#string

P698

20701787

http://www.w3.org/2001/XMLSchema#string

P932

2945137

http://www.w3.org/2001/XMLSchema#string